Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by State Street Corp

State Street Corp decreased its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 6.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,191,621 shares of the biopharmaceutical company's stock after selling 75,754 shares during the quarter. State Street Corp owned approximately 2.44% of Theravance Biopharma worth $9,604,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TBPH. China Universal Asset Management Co. Ltd. boosted its stake in Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 3,696 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Theravance Biopharma by 29.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company's stock valued at $137,000 after purchasing an additional 3,827 shares during the period. American Century Companies Inc. grew its stake in Theravance Biopharma by 11.7% during the 2nd quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company's stock worth $489,000 after buying an additional 6,026 shares during the last quarter. Martingale Asset Management L P grew its stake in Theravance Biopharma by 14.4% during the 3rd quarter. Martingale Asset Management L P now owns 54,450 shares of the biopharmaceutical company's stock worth $439,000 after buying an additional 6,870 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in Theravance Biopharma during the third quarter worth approximately $60,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Stock Down 2.7 %

TBPH traded down $0.27 on Friday, hitting $9.59. 121,179 shares of the company traded hands, compared to its average volume of 330,329. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $11.71. The company has a 50 day moving average of $9.34 and a 200-day moving average of $8.84. The stock has a market capitalization of $471.58 million, a PE ratio of -9.50 and a beta of 0.23.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $16.87 million for the quarter, compared to analysts' expectations of $16.11 million. During the same quarter last year, the company earned ($0.17) EPS. On average, research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 322,743 shares in the company, valued at $2,904,687. The trade was a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.90% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.